These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20620031)

  • 1. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
    de Klerk OL; Willemsen AT; Bosker FJ; Bartels AL; Hendrikse NH; den Boer JA; Dierckx RA
    Psychiatry Res; 2010 Aug; 183(2):151-6. PubMed ID: 20620031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
    de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
    Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
    Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
    Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
    Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.
    Takano A; Kusuhara H; Suhara T; Ieiri I; Morimoto T; Lee YJ; Maeda J; Ikoma Y; Ito H; Suzuki K; Sugiyama Y
    J Nucl Med; 2006 Sep; 47(9):1427-33. PubMed ID: 16954549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration.
    Bartels AL; Kortekaas R; Bart J; Willemsen AT; de Klerk OL; de Vries JJ; van Oostrom JC; Leenders KL
    Neurobiol Aging; 2009 Nov; 30(11):1818-24. PubMed ID: 18358568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil.
    Lee YJ; Maeda J; Kusuhara H; Okauchi T; Inaji M; Nagai Y; Obayashi S; Nakao R; Suzuki K; Sugiyama Y; Suhara T
    J Pharmacol Exp Ther; 2006 Feb; 316(2):647-53. PubMed ID: 16293715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-glycoprotein activity in the blood-brain barrier is affected by virus-induced neuroinflammation and antipsychotic treatment.
    Doorduin J; de Vries EF; Dierckx RA; Klein HC
    Neuropharmacology; 2014 Oct; 85():548-53. PubMed ID: 24973705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
    Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
    J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No inhibitory effect on P-glycoprotein function at blood-brain barrier by clinical dose of clarithromycin: a human PET study with [¹¹C]verapamil.
    Arakawa R; Ito H; Okumura M; Morimoto T; Seki C; Takahashi H; Takano A; Suhara T
    Ann Nucl Med; 2010 Feb; 24(2):83-7. PubMed ID: 20069466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Imaging blood-brain barrier function by using positron emission tomography to evaluate drug penetration into the brain].
    Takano H; Suhara T
    Brain Nerve; 2013 Feb; 65(2):137-43. PubMed ID: 23399671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.
    Liu L; Collier AC; Link JM; Domino KB; Mankoff DA; Eary JF; Spiekerman CF; Hsiao P; Deo AK; Unadkat JD
    Drug Metab Dispos; 2015 Nov; 43(11):1795-804. PubMed ID: 26354948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
    Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.
    Bartels AL; van Berckel BN; Lubberink M; Luurtsema G; Lammertsma AA; Leenders KL
    Parkinsonism Relat Disord; 2008 Aug; 14(6):505-8. PubMed ID: 18325822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
    van Assema DM; Lubberink M; Bauer M; van der Flier WM; Schuit RC; Windhorst AD; Comans EF; Hoetjes NJ; Tolboom N; Langer O; Müller M; Scheltens P; Lammertsma AA; van Berckel BN
    Brain; 2012 Jan; 135(Pt 1):181-9. PubMed ID: 22120145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
    Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
    Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.
    Bart J; Dijkers EC; Wegman TD; de Vries EG; van der Graaf WT; Groen HJ; Vaalburg W; Willemsen AT; Hendrikse NH
    Br J Pharmacol; 2005 Aug; 145(8):1045-51. PubMed ID: 15951832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Hsiao P; Bui T; Ho RJ; Unadkat JD
    Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
    Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
    Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.